Clinical trials: Colorectal Carcinoma (CRC)
Colorectal Neoplasms
A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer
This was a Phase 1, open-label, single-center study of CS-1008, an immunoglobulin G subclass 1 (IgG1) humanized monoclonal antibody, in subjects with advanced colorectal carcinoma who had received ≥ 1 prior chemotherapy regimen…
- Trial name
- NCT01220999
- Testing
- CS-1008
- Where
- Australia
- Volunteers
- 19 people
- Sponsor
- Ludwig Institute for Cancer Research
Colorectal Neoplasms
Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer
No ideal serum biomarker currently exists for the early diagnosis of colorectal cancer (CRC). Therefore, it is urgent that accurate and reliable serum biomarkers be identified.
- Trial name
- NCT01604798
- Testing
- Serum proteomics
- Where
- China
- Volunteers
- 547 people, healthy volunteers welcome
- Sponsor
- Fudan University
Metastatic Colorectal Cancer
Second-line Treatment of Metastatic Colorectal Cancer
The goal of this multicenter, single-arm, observational cohort study is to investigate the efficacy and safety of irinotecan in combination with trifluridine-tipiracil and bevacizumab in colorectal cancer with prior oxaliplatin…
- Trial name
- BEV-TASIRI (NCT06242067)
- Testing
- Trifluridine/tipiracil
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Qilu Hospital of Shandong University
Colorectal Neoplasms Malignant, Colonoscopy
Sensitivity of Fecal Immunochemical Test (FIT) for Colorectal Cancer (CRC) Screening
Fecal immunochemical test (FIT) was introduced in France late 2015, FIT has better diagnostic accuracy for colorectal cancers (CRCs) than previous screening tests.
- Conditions
- Colorectal Neoplasms Malignant, Colonoscopy, Early Detection of Cancer, Female
- Trial name
- FITBACK (NCT05163236)
- Testing
- Positive fecal immunochemical test (FIT), Negative fecal immunochemical test (FIT), Fecal immunochemical test (FIT) not performed
- Where
- France
- Volunteers
- 1,149 people
- Sponsor
- University Hospital, Brest
Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P03 monotherapy in adult…
- Conditions
- Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma
- Trial name
- NCT07169734
- Testing
- ALE.P03
- Where
- 41 sites in United States, France and 6 more
- Volunteers
- 180 people
- Sponsor
- Alentis Therapeutics AG
Colorectal Cancer Metastatic
Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer
The purpose of the present study is to investigate the benefit of anti-cancer therapy administered on the basis of drug sensitivity testing. This concerns colorectal cancer patients who have previously received standard treatment.
- Trial name
- NCT03251612
- Testing
- Based on sensitivity analysis
- Where
- 4 sites in Denmark, Germany
- Volunteers
- 90 people
- Sponsor
- Vejle Hospital
Breast Cancer, Pancreatic Cancer
Second Opinions in Oncology
The long-time goal is to understand what decision-making process and patient characteristics factor into a patient deciding to stay with their initial physician versus seeking treatment with a second opinion.
- Conditions
- Breast Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT05102500
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- University of Colorado, Denver
Metastatic Colorectal Cancer (CRC)
A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC
This is a Phase 3, multicenter, randomized and double-blind study assessing the interchangeability between TRS003 and China-approved Bevacizumab® (also called China-approved Avastin) for first-line treatment of patients with…
- Trial name
- CRC (NCT05378867)
- Testing
- TRS003, China-approved Bevacizumab, mFOLFOX6
- Volunteers
- 126 people
- Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
Advanced Colorectal Cancer
High Dose Simplified Folfiri in Advanced Colorectal Cancer: a Multicentre Phase II Study
A multicentre phase II study to evaluate the results of high dose simplified folfiri in advanced colorectal cancer
- Trial name
- NCT00286000
- Testing
- Administration of high dose simplified folfiri
- Where
- Belgium
- Volunteers
- 106 people
- Sponsor
- University Hospital, Ghent
Colorectal Cancer, Pancreatic Cancer
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
The overall goal of this feasibility study is to assess the initial safety and efficacy of LUM015 in ex vivo far-red imaging of colorectal, pancreatic, and esophageal cancers (adenocarcinoma) using the LUM Imaging System.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT02584244
- Testing
- LUM015, LUM 2.6 Imaging Device
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Lumicell, Inc.
Colorectal Neoplasms, Adenocarcinoma
Metformin Plus Irinotecan for Refractory Colorectal Cancer
MetIri seeks to identify if metformin combined to irinotecan can improve tumor control.
- Trial name
- NCT01930864
- Testing
- metformin, irinotecan
- Where
- 2 sites in Brazil
- Volunteers
- 41 people
- Sponsor
- Barretos Cancer Hospital
Colorectal Cancer
Effect of Multimodal Prehabilitation After Colorectal Cancer Surgery
The process of enhancing an individual's functional capacity to optimize physiologic reserves before an operation to withstand the stress of surgery has been coined prehabilitation.
- Trial name
- NCT05854394
- Testing
- Multimodal prehabilitation management Multimodal prehabilitation management
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xiamen University
Patient Preference
Tradeoffs in Patient Decision Making About Rectal Cancer Treatment: Benefits Compared to Quality Of Life.
This study is aiming to look into patients' treatment preferences and their socio economic background as well as the exploration of thought processes leading to these preferences.
- Trial name
- Pathos (NCT04925154)
- Testing
- The only intervention will be the information brochure that will be given after the first questionnaire.
- Where
- Canada
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Colorectal Cancer
Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy
This is a prospective, multicenter, randomized, parallel controlled study to evaluate the effectiveness of Huaier Granule in preventing recurrence and metastasis after radical resection of colorectal cancer
- Trial name
- NCT06090994
- Testing
- Huaier granule, Capecitabine
- Where
- 9 sites in China
- Volunteers
- 756 people
- Sponsor
- Fudan University
Minimal Residual Disease, Adjuvant Chemotherapy
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
To find out if a combination of fruquintinib and tislelizumab can control CRC in patients who have received treatment for the disease but still have "positive" ctDNA tests for MRD (meaning there is evidence of MRD based on this…
- Conditions
- Minimal Residual Disease, Adjuvant Chemotherapy, Colorectal Cancer, Fruquintinib
- Trial name
- NCT07136077
- Testing
- Tislelizumab, Fruquintinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Colorectal Cancer
Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer
The primary objective of this study is to assess the effect of treatment with ABX-EGF on best overall objective response rate by modified RECIST (confirmed complete or partial response) in Japanese subjects with metastatic…
- Trial name
- NCT00327119
- Testing
- ABX-EGF (panitumumab)
- Volunteers
- 50 people
- Sponsor
- Amgen
Colorectal Cancer, Colon Cancer
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
This study has two portions. The main goal of the Phase I portion of this research study is to see what doses of CB-839 and capecitabine can safely be given to patients without having too many side effects.
- Conditions
- Colorectal Cancer, Colon Cancer, Rectal Cancer, Solid Tumor
- Trial name
- NCT02861300
- Testing
- CB-839, Capecitabine
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- David Bajor, MD
Gastric and Colorectal Cancer
A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy
This study is a prospective single-arm phase II clinical study. Advanced gastric and colorectal tumor patients with FGFR 1-3 alterations who have failed standard therapy will be enrolled in this study once they have signed the…
- Trial name
- NCT05202236
- Testing
- pemigatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction
Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction
RATIONALE: The use of endoscopy to place a metal stent in the large intestine is less invasive than surgery for treating cancer-related bowel obstruction and may have fewer side effects and improve recovery.
- Conditions
- Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Gastric Cancer, Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00004911
- Testing
- bowel obstruction management, quality-of-life assessment
- Where
- United States
- Sponsor
- Northwestern University
Colorectal Cancer, Anastomosis
Safe Anastomosis Feasibility Study
A clinical trial to assess the efficacy, mechanism of action and safety of the Colovac+ Colorectal Anastomosis Protection Device in providing temporary protection of the anastomosis in subjects undergoing lower anterior resection…
- Trial name
- SAFE2019 (NCT05180565)
- Testing
- Colovac
- Where
- 7 sites in Belgium, France
- Volunteers
- 27 people
- Sponsor
- SafeHeal Inc
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.